Virginia Kaklamani, MD
Medical Oncology · San Antonio, TXNPI 1841235439
Payments from drug & device makers
Across 1,150 payments — averaging $4756.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1M
- Daiichi Sankyo Inc.$1M
- Genentech, Inc.$913K
- Eli Lilly$725K
- Gilead$372K
- Radius Health, Inc.$286K
- plus $1.2M from 27 others
Across 12 payments — averaging $717.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$7K
- Radius Health, Inc.$1K
- F. Hoffmann-la Roche AG$304
- Novartis$223
What the payments were for
- Consulting fees$245,14731%
- Speaking & faculty fees$496,99063%
- Grants$2500%
- Travel & lodging$35,7295%
- Food & beverage$7,5021%
- Education$850%
- Other$1,7470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 87 | $1,003,534 |
| Daiichi Sankyo Inc. | 170 | $1,001,013 |
| Genentech, Inc. | 119 | $912,611 |
| Eli Lilly | 23 | $725,224 |
| Gilead | 142 | $372,266 |
| Radius Health, Inc. | 33 | $286,256 |
| Eisai Inc. | 159 | $257,413 |
| Daiichi Sankyo Company LTD | 29 | $224,533 |
| Stemline Therapeutics Inc. | 59 | $157,845 |
| Pfizer(2 entities) | 42 | $91,194 |
| AstraZeneca | 90 | $77,541 |
| Genentech USA, Inc. | 29 | $52,614 |
| Puma Biotechnology, Inc. | 40 | $40,241 |
| Merck | 8 | $38,939 |
| Lilly USA, LLC | 13 | $35,382 |
| Bristol Myers Squibb | 21 | $34,318 |
| Biontech SE | 8 | $31,994 |
| Tesaro, Inc. | 11 | $27,893 |
| Seagen Inc. | 24 | $23,450 |
| GSK | 6 | $19,888 |
| Roche Products Limited | 1 | $16,250 |
| Hoffmann-la Roche Limited | 3 | $12,763 |
| Immunomedics, Inc. | 8 | $10,000 |
| Tersera Therapeutics LLC | 7 | $5,524 |
| Sirtex Medical Inc | 3 | $3,348 |
| Sanofi | 1 | $2,517 |
| Athenex Pharmaceutical Division, LLC | 4 | $2,000 |
| F. Hoffmann-la Roche AG | 2 | $1,855 |
| Bayer | 1 | $1,199 |
| Amgen | 3 | $61 |
| AVEO Pharmaceuticals, Inc. | 1 | $43 |
| Tempus AI, Inc | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Trodelvy$222,305
- Enhertu$65,045
- TALZENNA$52,009
- KISQALI$51,421
- Orserdu$45,514
- Nerlynx$39,782
- PIQRAY$36,780
- Phesgo$35,099
- Abraxane$32,733
- IBRANCE$31,130
- VERZENIO$26,389
- Kadcyla$23,663
- TUKYSA$23,450
- LYNPARZA$8,355
- Halaven$5,625
- ZOLADEX$5,487
- Perjeta$4,950
- SIR-Spheres Microspheres$3,348
- TECENTRIQ$3,015
- Oral Paclitaxel$2,000
How this compares
$5,469,772 in reported general payments places this provider in the 85th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 63 | $1,086,298 |
| IbrancePalbociclib | 62 | $957,260 |
| OrserduElacestrant Hcl | 15 | $349,352 |
| TruqapCapivasertib | 15 | $344,274 |
| TalzennaTalazoparib Tosylate | 11 | $202,400 |
| Exemestane | 56 | $10,395 |
| Anastrozole | 463 | $8,119 |
| VeozahFezolinetant | 11 | $5,888 |
| Letrozole | 82 | $1,772 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 48 | $1,366 |
| Prochlorperazine Maleate | 55 | $977 |
| Alendronate Sodium | 105 | $928 |
| Morphine Sulfate ErMorphine Sulfate | 24 | $755 |
| Tamoxifen Citrate | 29 | $633 |
| Ondansetron Hcl | 20 | $468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Talzenna | $91,194 | $1,159,66073 claims |
| NovartisKisqali | $1,003,534 | $1,086,29863 claims |
| Stemline Therapeutics Inc.Orserdu | $157,845 | $349,35215 claims |
| AstraZenecaTruqap | $77,541 | $344,27415 claims |
| Lilly USA, LLCOlanzapine | $35,382 | $7617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 495 medical oncology providers in Texas.
Other medical oncology in San Antonio
- Amita PatnaikSan Antonio$17.8M
- Anthony TolcherSan Antonio$15.9M
- Sukeshi AroraSan Antonio$9.1M
- John SarantopoulosSan Antonio$9M
- Lei ZhengSan Antonio$5.3M
- Hagop KantarjianHouston$100.5M
- Timothy YapHouston$56.7M
- Yasir ElaminHouston$41.3M
- David HongHouston$31.6M
- Guillermo Garcia-ManeroHouston$31.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.